CTRI/2023/12/060636尚未招募3 期
A RANDOMISED SINGLE-BLIND,TWO- ARM CLINICAL STUDY COMPARING THE EFFICACY, SAFETY OF STANDARD UNANI FORMULATION WITH CLOTRIMAZOLE 1% CREAM IN THE TREATMENT OF QOOBA(TINEA CRURIS). - NI
PG Department of Moalijat0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Age between 12 months - 80 years
- •Clinically diagnosed patients of qooba (times cruris)
- •Patients who have signed the informed consent form
排除标准
- •Patients suffering from concomitant diseases like psoriasis, eczema
- •Patients suffering from infection diseases
- •Patients suffering from severe systemic and metabolic diseases
- •Diabetic and hypertensive patients
- •STD diseases diagnosed patients
- •Pregnant and lactating women
研究者
相似试验
尚未招募
3 期
To study the effect of unani medicine in piles.CTRI/2023/12/060627Government Nizamia Tibbi College and General Hospital
尚未招募
2 期
A clinical study on the management of type 2 Diabetes Mellitus with Nisha katakadi Niruha basti and Dhanvantaram ghritha Matrabasti followed by Saptachakra Kashaya as shamanoushadi with two parellel groups A and B respctively with which only patient is blinded.CTRI/2019/07/020314Rajiv Gandhi University of Health Sciences Bengaluru
尚未招募
1 期
Oral medicine trial for COVID 19CTRI/2020/09/027616RGUHS Bangalore
进行中（未招募）
不适用
sing Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsMedDRA version: 17.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMultiple SclerosisEUCTR2013-001439-34-DEGenzyme Corporation1,000
进行中（未招募）
1 期
sing Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsMultiple SclerosisEUCTR2013-001439-34-ESGenzyme Corporation1,001